CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Natalizumab

Natalizumab

Last Updated: October 26, 2006

Result type: Reports

Project Number: SR0082-000

Product Line: Reimbursement Review

Generic Name: Natalizumab

Brand Name: Tysabri

Manufacturer: Biogen Idec Canada Inc.

Therapeutic Area: Multiple Sclerosis, relapsing-remitting

Indications: Multiple Sclerosis, relapsing-remitting

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 26, 2007

Recommendation Type: Do not list

Natalizumab

Files